User doing PRP with exosomes for hair loss, sees possible regrowth after two treatments. Another user suggests providing before and after pictures for better assessment.
The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.
A user shared their positive experience with a 4750 graft hair transplant at Dr. Orçun Clinic in Istanbul, including a high-quality exosome treatment. Despite skepticism and accusations of advertising, the user expressed satisfaction with the natural-looking results and the doctor's personal involvement.
A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.
PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
Using PP405 and Clascoterone after a hair transplant may not cause issues if the transplant didn't achieve native density, but could lead to competition for blood supply if it did. Some users suggest waiting for these drugs to be available, as they might not significantly impact blood supply or regrowth.
The conversation is about improving scalp appearance by regaining adipose tissue and making the skin look better using scalp massages and a moisturizer with hyaluronic acid, ceramides, and urea. The user is not trying to regrow hair but wants to improve the scalp's thickness and appearance.
A user's father experienced hair regrowth and other health improvements after two IV exosome treatments. The user also had four rounds of exosome therapy, noting significant hair regrowth and relief from headaches, but no change in gray hair.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
A user is exploring VEGF gene therapy to enhance hair transplant results, considering measuring hair shaft diameter and growth rate. Suggestions include using phototrichograms and possibly adding PRP, though its effectiveness is uncertain.
Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.
The conversation discusses promising hair cloning research seeking commercialization partners. Cultured hairs formed with pigment, indicating positive progress.
Lichen Planopilaris (LPP), a form of permanent hair loss, which can be mistaken for seborrheic dermatitis and is characterized by scalp itching, burning, redness, and dandruff. Treatment options discussed include steroidal creams, finasteride, minoxidil, and RU58841.
The user is unsatisfied with their hair transplant and is considering another transplant, PRP, exosomes, or stem cells. They currently use topical minoxidil, dutasteride, and tretinoin.
The conversation is about a user sharing their positive experience with Scalp Micropigmentation (SMP) for hair loss, highlighting the natural look achieved by a specialized artist. The procedure cost $2600 and was done by Alex Corona in Panama City Beach, FL.
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
Oleic acid and microneedling are being explored for hair regrowth, but results are mixed. Addressing DHT and fibrosis is crucial, with treatments like finasteride, minoxidil, and scalp massage also discussed.
PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
A new human trial using an FDA-approved treatment for wound healing called Verteporfin, which may potentially be able to reverse scarring and regrow hair in that area. The trial is only lasting one month so far.
A user developed AI software to simulate hair transplants on photos, helping people visualize potential results. The tool offers photo-realistic renderings but advises caution regarding exact outcomes due to various factors.
The conversation discusses the effectiveness of Regenera Activia stem cells versus Cellgenic exosomes for hair loss treatment. The user has been using topical minoxidil 5% and 0.001% estradiol for a year without results.
PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.
The conversation is about enhancing dermarolling for hair loss by using topical peptides like tb-500 or GHK-Cu to aid in healing and hair growth, and whether anyone has experienced significant results from this method.
OP injured their temple using derma rolling and tretinoin, causing peeling and potential hair follicle damage. Users suggest the injury might be permanent, possibly resulting in scar tissue where hair won't grow.
The user is 10 days post-hair transplant, pleased with the results so far, and hopes for increased density. The procedure was done at Vanity Hospital in Istanbul, with around 3400-3750 grafts used.